Fritextsökning
Innehållstyper
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Speed meets precision for high-density components
ZEISS METROTOM 800 320 kV.
-
She is CSL Behring's new Nordic General Manager
Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.
-
Scientific Solutions
-
From powder to implant
Quality assurance for additively manufactured implants.
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...
-
Scale Up Your Image Analysis
ZEISS arivis Hub for accelerated analysis and faster results.
-
Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy
Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
Investment CEO: “The Nordics are outstanding in creating successful medtech companies”
Since the beginning of last month, Susanna Francke Rodau has been a partner and the new CEO of Segulah Medical Acceleration, which invests in medical technology...
-
Quretech granted a European patent for a new type of antibiotic
The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.
-
Quality assurance for research and development of medical devices
Overcome the hurdles of research, development, and QA lab environments within the regulated medical technology industry.
-
Your solution for right part positioning
ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.
-
Webinar: Support Trial Patients Transitioning to the Commercial Space
Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.
-
Bioscience – Groundbreaking Research & Diagnostics: Stockholm
-
The art of successful licensing – “A lot has to align”
Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies...
-
Lund University’s record-breaking recruitment – attracting researchers from around the world
The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...
-
Novo Nordisk establishes new factory in Denmark
Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.
-
ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin
More than 50 distinguished speakers from leading manufacturing companies.
-
How to avoid measurement inaccuracies due to wear
Expert tip from ZEISS.
-
Digital Temperature Sensors from ZEISS
New Metrology Expert Tip video.
-
Life science trends 2025 – Part 1 obesity drugs
More obesity drugs are being launched this year following Novo Nordisk and Eli Lilly's previous successes with GLP-1 drugs. But the next big breakthrough in obe...
-
Large study: The benefits and risks of obesity medications
Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...